MedTrace Logo

Avatrombopag to Promote Platelet Engraftment After Allo-HSCT

NCT05143892 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2022-12-23

No results posted yet for this study

Summary

The purpose of the study is to evaluate the efficacy and safety of avatrombopag for the promotion of platelet engraftment after Allo-HSCT.

Conditions

  • Platelet Disorder

Interventions

DRUG

Avatrombopag

Avatrombopag administered at the described frequency to achieve a target platelet count

OTHER

Supportive care

Supportive care other than TPO-RAs or recombinant human thrombopoietin.

Sponsors & Collaborators

  • The First Affiliated Hospital of Soochow University

    lead OTHER

Principal Investigators

  • Yue Han · The First Affiliated Hospital of Soochow University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-12-31
Completion
2023-11-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05143892 on ClinicalTrials.gov